18.11.2024 • News

CEFIC Re-elects Ilham Kadri as President

Ilham Kadri, CEO of Syensqo, has been re-elected as president of CEFIC, the European Chemical Industry Council, for a two-year term, effective immediately.

“It is an honor to serve this extraordinary industry at such a critical time. Together, we are proving the power of partnership, driving innovation, and tackling Europe’s greatest challenges – from climate change to industrial resilience. The world is watching Europe, and the chemical industry – ‘the mother of all industries’ – is the foundation of a sustainable and competitive future. My commitment remains firm: to support our sector’s transition while ensuring Europe remains a competitive hub for innovation, investment, and opportunity,” Kadri said.

According to CEFIC, Kadri will also take on the role of president of the International Council of Chemical Associations (ICCA) on Jan. 1, 2025, during CEFIC’s two-year mandate.

Marco Mensink, CEFIC director general, commented: “Ilham’s passion and commitment to our sector are unmatched. She has inspired a united vision within CEFIC and strengthened our relationships with Europe’s key decision-makers. Her leadership gives our sector a strong voice as we advocate for practical solutions that keep Europe competitive and sustainable.”

Ilham Kadri, CEO of Syensqo, has been re-elected as president of the European...
Ilham Kadri, CEO of Syensqo, has been re-elected as president of the European Chemical Industry Council, CEFIC | © Syensqo/CEFIC

Company

Logo:

European Chemical Industry Council - Cefic aisbl

Avenue Van Nieuwenhuyse 4
1160 Brüssel
Belgium

Company contact







Virtual Event

High Performance Food Production
Perfection Starts in the Tank

High Performance Food Production

March 24, 2026 | Optimize your food production with smarter mixing—join the Ystral seminar to discover 20 real-world applications that cut processing times, reduce costs, and boost product quality.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read